Matricelf

Company Overview

Snapshot

Founded in April 2019 by Alon Sinai, Matricelf operates with 11–50 employees. The company has raised over $10 million across four funding rounds. Matricelf went public on the TASE in June 2021, marking a significant milestone in its journey to commercialize regenerative medicine.

Business overview

Matricelf is a Health Tech & Life Sciences company specializing in personalized autologous regenerative medicine. The company has developed a proprietary technology that produces engineered tissue from a patient's own omental biopsies, composed of matrix and cells. This technology, licensed from Tel Aviv University, was instrumental in the first-ever 3D printing of a human heart from human cells and matrix. Matricelf's platform aims to treat a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, by creating functional tissue implants.

Strategic signal

In June 2026, Matricelf initiated an IND-enabling efficacy study following positive preclinical results in spinal cord injury, signaling a critical advancement towards human clinical trials. This development, coupled with the initiation of a GMP manufacturing program in June 2026 and successful GLP safety study completion in June 2026, indicates strong progress in de-risking its core technology and moving closer to commercialization for spinal cord injury treatments. These milestones collectively underscore the company's commitment to bringing its personalized regenerative therapies to patients.

Company Intelligence Q&A

What is Matricelf's core technology?

Matricelf's core technology involves a proprietary decellularization process that separates stromal cells and extracellular matrix (ECM) from a small omental biopsy sample. A thermo-responsive hydrogel is produced from the ECM, and stromal cells are reprogrammed into induced pluripotent stem cells (iPSCs) which are then incorporated into the hydrogel and differentiated into desired functional tissue.

When did Matricelf go public?

Matricelf went public on the TASE in June 2021.

What was a significant recent development in Matricelf's spinal cord injury program?

In June 2026, Matricelf initiated an IND-enabling efficacy study following positive preclinical results in spinal cord injury. This step is crucial for advancing its personalized engineered tissue implants towards human trials.

What strategic collaborations has Matricelf recently announced?

In March 2026, Matricelf entered a strategic collaboration with the CiRA Foundation in Japan to advance next-generation regenerative manufacturing. Additionally, in March 2026, Matricelf announced a strategic collaboration with Sheba Medical Center to advance its first-in-human clinical program in spinal cord injury.

What is Matricelf's focus for Parkinson's disease therapy?

In March 2026, Matricelf signed a Memorandum of Understanding (MOU) to establish a subsidiary dedicated to the commercialization of Parkinson's disease therapy.